A study of 39,184 people with solid tumors, published Oct. 8, 2026, found that about 1 in 6 had an inherited genetic change that increased their cancer risk. Testing only people under 50 would have missed 72% of those with these changes.
News|Articles|September 25, 2026
5 Years of FDA Approvals in Lymphoma: Who They've Helped and What Comes Next
Author(s)Quincy Attobrah
Fact checked by: CURE staff
See how FDA-approved lymphoma treatments have changed over 5 years — what's new, who it's helped, and what's still to come.
Advertisement
Advertisement
Five years ago, if standard chemotherapy and immunotherapy had stopped working for your lymphoma, CAR-T cell therapy was still brand new and available at only a handful of specialized centers. Today, an entirely different category of drug — the bispecific antibody — didn't exist for lymphoma at all in 2021, and now covers multiple lymphoma types with several FDA-approved drugs to pick from. Here's a look at exactly what the FDA has approved, year by year, and what it's actually meant for patients along the way, told partly through CURE's own reporting.
Related to this article
Updated NCCN guidelines for mantle cell lymphoma favor BTK inhibitor pills in first treatment and say people with no detectable lymphoma after treatment can skip a stem cell transplant.
California Gov. Gavin Newsom signed AB 1682 on Sept. 27, requiring large-group health plans to cover prescribed scalp cooling starting Jan. 1, 2027. Medi-Cal coverage is pending federal approval.
In the phase 3 ASAC trial, daily aspirin did not lower the risk of colorectal cancer returning after treatment for liver metastases, and serious side effects were more common.
The FDA withdrew Zepzelca’s accelerated approval for small cell lung cancer after the LAGOON trial failed to show longer survival. Its maintenance use with Tecentriq is unaffected.
Liver and bile duct cancer treatment has changed quickly since 2021, with new immunotherapy combinations, targeted pills and a new radiation option. Here's what's been approved and what it means for patients.
In the phase 3 MAVERICK trial, people with small cell lung cancer who had regular brain MRIs instead of preventive whole-brain radiation kept their memory and thinking intact longer, with no clear survival difference so far.
ASTRO’s first bladder cancer radiation guideline supports trimodal therapy as an alternative to bladder removal for select patients with muscle-invasive disease.
Advertisement
Advertisement